International, Multicenter, Open-label, Phase II Study to Investigate the Efficacy and Safety of Multiple Doses of IMAB362 in Patients With Advanced Adenocarcinoma of the Stomach or the Lower Esophagus.
Phase of Trial: Phase II
Latest Information Update: 05 Jan 2018
At a glance
- Drugs Claudiximab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Ganymed Pharmaceuticals
- 17 Dec 2015 Status changed from active, no longer recruiting to completed.
- 08 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov
- 27 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.